Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

1.

Cytochrome P450 2J2 promotes the neoplastic phenotype of carcinoma cells and is up-regulated in human tumors.

Jiang JG, Chen CL, Card JW, Yang S, Chen JX, Fu XN, Ning YG, Xiao X, Zeldin DC, Wang DW.

Cancer Res. 2005 Jun 1;65(11):4707-15.

2.

Epoxyeicosatrienoic acids, cell signaling and angiogenesis.

Fleming I.

Prostaglandins Other Lipid Mediat. 2007 Jan;82(1-4):60-7. Epub 2006 Jul 11. Review.

PMID:
17164133
3.

Cytochrome P450 epoxygenase CYP2J2 and the risk of coronary artery disease.

Spiecker M, Liao J.

Trends Cardiovasc Med. 2006 Aug;16(6):204-8. Review.

PMID:
16839864
4.

Cytochrome P450 2J2: distribution, function, regulation, genetic polymorphisms and clinical significance.

Xu M, Ju W, Hao H, Wang G, Li P.

Drug Metab Rev. 2013 Aug;45(3):311-52. doi: 10.3109/03602532.2013.806537. Review.

PMID:
23865864
5.

Cytochrome p450 and vascular homeostasis.

Fleming I.

Circ Res. 2001 Oct 26;89(9):753-62. Review.

6.

The roles of CYP450 epoxygenases and metabolites, epoxyeicosatrienoic acids, in cardiovascular and malignant diseases.

Xu X, Zhang XA, Wang DW.

Adv Drug Deliv Rev. 2011 Jul 18;63(8):597-609. doi: 10.1016/j.addr.2011.03.006. Epub 2011 Apr 6. Review.

PMID:
21477627
7.
8.

CYP epoxygenase derived EETs: from cardiovascular protection to human cancer therapy.

Chen C, Wang DW.

Curr Top Med Chem. 2013;13(12):1454-69. Review.

PMID:
23688135
9.

Roles of the epoxygenase CYP2J2 in the endothelium.

Askari A, Thomson SJ, Edin ML, Zeldin DC, Bishop-Bailey D.

Prostaglandins Other Lipid Mediat. 2013 Dec;107:56-63. doi: 10.1016/j.prostaglandins.2013.02.003. Epub 2013 Mar 6. Review.

10.

EET signaling in cancer.

Panigrahy D, Greene ER, Pozzi A, Wang DW, Zeldin DC.

Cancer Metastasis Rev. 2011 Dec;30(3-4):525-40. doi: 10.1007/s10555-011-9315-y. Review.

11.

HETEs/EETs in renal glomerular and epithelial cell functions.

Natarajan R, Reddy MA.

Curr Opin Pharmacol. 2003 Apr;3(2):198-203. Review.

PMID:
12681244
12.

From endothelium-derived hyperpolarizing factor (EDHF) to angiogenesis: Epoxyeicosatrienoic acids (EETs) and cell signaling.

Michaelis UR, Fleming I.

Pharmacol Ther. 2006 Sep;111(3):584-95. Epub 2005 Dec 27. Review.

PMID:
16380164
13.

Epoxyeicosatrienoic acids: formation, metabolism and potential role in tissue physiology and pathophysiology.

Kaspera R, Totah RA.

Expert Opin Drug Metab Toxicol. 2009 Jul;5(7):757-71. doi: 10.1517/17425250902932923. Review.

PMID:
19505190
14.

Genetic variation in the cytochrome P450 epoxygenase pathway and cardiovascular disease risk.

Theken KN, Lee CR.

Pharmacogenomics. 2007 Oct;8(10):1369-83. Review.

PMID:
17979511
15.

Expression of cytochrome P450 in tumor tissues and its association with cancer development.

Oyama T, Kagawa N, Kunugita N, Kitagawa K, Ogawa M, Yamaguchi T, Suzuki R, Kinaga T, Yashima Y, Ozaki S, Isse T, Kim YD, Kim H, Kawamoto T.

Front Biosci. 2004 May 1;9:1967-76. Review.

PMID:
14977602
16.

Inhibition and inactivation of human CYP2J2: Implications in cardiac pathophysiology and opportunities in cancer therapy.

Karkhanis A, Hong Y, Chan EC.

Biochem Pharmacol. 2017 Feb 23. pii: S0006-2952(17)30094-1. doi: 10.1016/j.bcp.2017.02.017. [Epub ahead of print] Review.

PMID:
28237650
17.

Cellular heterogeneity in human epithelial neoplasms.

Mackillop WJ, Dotsikas G.

Int J Cell Cloning. 1988 May;6(3):161-78. Review.

PMID:
3294306

Supplemental Content

Support Center